GCP
IMRX icon

GSA Capital Partners’s Immuneering IMRX Stock Holding History

GSA Capital Partners’s Portfolio IMRX Stock Details IMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.71M Buy
343,303
+266,551
+347% +$1.35M 0.11% 221
2026
Q1 		$404K Buy
+76,752
New +$393K 0.03% 1052
2025
Q4 		– Sell
-37,836
Closed -$265K – 1860
2025
Q3 		$265K Buy
+37,836
New +$196K 0.02% 1271
2023
Q1 		– Sell
-23,371
Closed -$113K – 1683
2022
Q4 		$113K Sell
23,371
-9,739
-29% -$86.3K 0.01% 1290
2022
Q3 		$474K Buy
+33,110
New +$263K 0.06% 608

Other funds holding IMRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DA
DCF Advisers Greenwich, Connecticut $566M AUM 197.74% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

GSA Capital Partners's IMRX Position: Q2 2026 in Review

GSA Capital Partners increased its Immuneering (IMRX) stake by 347% in Q2 2026, buying an estimated $1.35M and bringing the position to 343,303 shares worth $1.71M. The position accounts for 0.11% of the portfolio, ranked #221.

GSA Capital Partners first reported a position in IMRX in Q3 2022 and has held it in 5 quarters since. 112 funds tracked by Wall St. Rank hold IMRX as of Q2 2026.

  • GSA Capital Partners held 343,303 shares of Immuneering worth $1.71M as of Q2 2026.
  • GSA Capital Partners bought 266,551 Immuneering shares in Q2 2026, an estimated $1.35M.
  • Immuneering made up 0.11% of GSA Capital Partners's portfolio in Q2 2026, its #221 holding.
  • GSA Capital Partners first reported a position in Immuneering in Q3 2022 and has held it in 5 quarters since.
  • 112 funds tracked by Wall St. Rank held Immuneering as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.